氧化苦参碱对非酒精性脂肪性肝病大鼠肝脏保护作用研究*

目的 观察氧化苦参碱(OMT)干预对非酒精性脂肪性肝病(NAFLD)大鼠肝脏的保护作用。方法 随机将40只SD大鼠分为对照组10只、模型组10只、OMT干预组10只和辛伐他汀干预组10只,采用高脂饮食饲养建立NAFLD模型,自第9 w开始分别给予OMT或辛伐他汀灌胃至16 w。采用ELISA法检测血清白细胞介素-1β(IL-1β)、IL-6、IL-10和肿瘤坏死因子-α(TNF-α)水平。取肝组织匀浆,检测超氧化物歧化酶(SOD)、还原型谷胱甘肽(GSH)和丙二醛(MDA)水平。结果 OMT干预组大鼠体质量和肝质量分别为(610.3±9.4)g和(11.6±0.7)g,显著低于模型组【分别为(631.8±13.9)g和(13.9±0.6)g,P<0.05】;血清ALT和AST水平分别为(78.9±7.0)U/L和(120.4±11.3)U/L,显著低于模型组【分别为(96.7±11.4)U/L和(183.1±25.9)U/L,P<0.05】;血清TC、TG和LDL水平分别为(2.0±0.2)mmo/L、(2.2±0.1)mmo/L和(1.0±0.1)mmo/L,显著低于模型组【分别为(2.4±0.2)mmo/L、(2.8±0.2)mmo/L和(1.2±0.2)mmo/L,P<0.05】;血清IL-1β、IL-6和TNF-α水平分别为(6.4±1.8)pg/ml、(63.7±8.5)pg/ml和(13.9±1.9)pg/ml,显著低于模型组【分别为(13.9±8.4)pg/ml、(149.8±12.0)pg/ml和(36.5±2.9)pg/ml,P<0.05】,而血清IL-10水平为(42.3±2.0)pg/ml,显著高于模型组【(18.9±1.9)pg/ml,P<0.05】;肝组织匀浆SOD和GSH水平分别为(22.3±2.1)μg/mg和(26.0±2.1)U/mg,显著高于模型组【分别为(17.5±1.9)μg/mg和(15.8±1.8)U/mg,P<0.05】,而MDA水平为(17.9±2.2)nmol/mg,显著低于模型组【(23.8±2.7)nmol/mg,P<0.05】。结论 氧化苦参碱可有效保护NAFLD大鼠肝功能,降低血脂水平,可能与其抗炎和抗氧化应激作用有关。

Protective effect of oxymatrine on liver steatosis in rats with high-fat-induced non-alcoholic fatty liver diseases

Objective The aim of this experiment was to observe the protective effect of oxymatrine (OMT) on liver steatosis in rats with high-fat-induced non-alcoholic fatty liver diseases (NAFLD). Methods 40 SD rats were randomly divided into control, model, OMT –intervened and simvastatin-intervened groups, with 10 rats in each. The NAFLD model was established by high-fat diet feeding. Since 9^th week, the normal saline, OMT or simvastatin was given by gavage, and the management continued to 16^th week. Serum interleukin-1β (IL-1β), IL-6, IL-10 and tumor necrosis factor-α (TNF-α), and liver homogenate superoxide dismutase (SOD), reduced glutathione (GSH) and malondialdehyde (MDA) levels were detected. Results The body mass and liver mass in OMT-intervened group were(610.3±9.4)g and (11.6±0.7)g, significantly lower than (631.8±13.9)g and (13.9±0.6)g, respectively, P<0.05] in the model; serum ALT and AST levels were(78.9±7.0)U/L and (120.4±11.3)U/L, significantly lower than (96.7±11.4)U/L and (183.1±25.9)U/L, respectively, P<0.05] in the model; serum TC, TG and LDL levels were (2.0±0.2)mmo/L, (2.2±0.1)mmo/L and (1.0±0.1)mmo/L, significantly lower than (2.4±0.2)mmo/L, (2.8±0.2)mmo/L and (1.2±0.2)mmo/L, respectively, P<0.05] in the model group; serum IL-1β, IL-6 and TNF-α levels were (6.4±1.8)pg/ml, (63.7±8.5)pg/ml and (13.9±1.9)pg/ml, significantly lower than (13.9±8.4)pg/ml, (149.8±12.0)pg/ml and (36.5±2.9)pg/ml, respectively, P<0.05], while serum IL-10 level was (42.3±2.0) pg/ml, significantly higher than (18.9±1.9)pg/ml, P<0.05] in the model; the liver homogenate SOD and GSH levels were (22.3±2.1)μg/mg and (26.0±2.1)U/mg, significantly higher than (17.5±1.9)μg/mg and (15.8±1.8)U/mg, respectively, P<0.05] while MDA level was (17.9±2.2)nmol/mg, significantly lower than (23.8±2.7)nmol/mg, P<0.05] in the model. Conclusion Oxymatrine could protect the liver function of rats with NAFLD and reduce blood lipids levels, which might be related to its anti-inflammatory and anti-oxidative stress effects.